Autolus Therapeutics plc ADR

AUTLNASDAQ · USD
1.86USD0.00 (-2.88%)
1210

Autolus Therapeutics plc ADR (AUTL) Option Chain

As of September 25, 2026, Autolus Therapeutics plc ADR is trading at $1.86, a -2.88% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 189.9%. IV Rank is 41%.

Read more

Tracking the AUTL option chain helps you see every strike and expiry on Autolus Therapeutics plc ADR in one view, so you can quickly identify the contracts that fit your thesis and your risk. Autolus Therapeutics plc ADR's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of AUTL options activity at a glance. Use our scanner to monitor the AUTL option chain in real time and filter for the AUTL options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For AUTL stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the AUTL option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where AUTL stock options are being actively traded and where they are not.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Autolus Therapeutics plc ADR's full chain across every expiry, highlights the most liquid strikes, and lets you screen AUTL options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of AUTL stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile53.57% Neutral
  • Market cap (M$)494
  • 52 weeks high-27.91%
  • 52 weeks low57.63%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$8.42
    352.69% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-11
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.05
  • EPS growth next 5 years26.30%

As of September 25, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
0.36000.041.360.901.900.50-73.12—1.000.001.000099.64
12.47200.040.860.401.401.00-46.24—1.000.001.000087.53
39.94000.240.360.101.101.50-19.35—1.000.001.000060.06
64.8622740.950.00—0.952.00+7.53—1.000.140.860035.14
80.92001.000.00—1.002.50+34.410.251.250.640.11010219.08

As of September 25, 2026

Scan the full option chain in one place

Browse the full AUTL option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial